Respiratory Syncytial Virus Immune Globulin Intravenous (Systemic)
Brand Names : RespiGam, RSV-IGIV
- Immunizing agent (passive)
Respiratory syncytial virus
immune globulin intravenous (res-pi-ra-TOR-e SIN-sish-al
VI-ras im-MUNE GLOB-yoo-lin IN-tra-ve-nas) (RSV-IGIV) belongs
to a group of medicines known as immunizing agents. RSV-IGIV is used to prevent
infection caused by respiratory syncytial virus (RSV). RSV-IGIV works by giving
your body the antibodies it needs to protect it against RSV infection.
RSV infection can cause serious problems, such as pneumonia and bronchitis,
which affect the lungs; and in severe cases, even death. These problems are
more likely to occur in infants and young children less than 6 months of age
with chronic lung disease, those born with heart problems, and those with
a history of premature birth.
Onset of RSV activity usually occurs in November and continues through
April or early May, with peak activity occurring from late January through
mid-February. A good way to help prevent RSV infection is to get RSV-IGIV
before the start of the RSV season.
RSV-IGIV is used to prevent serious lower respiratory tract infection caused
by the respiratory syncytial virus (RSV) in children less than 24 months of
age with breathing problems or a history of premature birth.
RSV-IGIV is to be administered only by or under the supervision of your
doctor or other health care professional. It is available in the following
Injection (U.S. and Canada)
Some commonly used brand names are:
In the U.S. -
In Canada -
Another commonly used name is RSV-IGIV